Skip to main content

Table 5 Medications prescribed at study start (N = 64) and study end (N = 63)

From: Early identification and preventive care for elevated cardiovascular disease risk within a remote Australian Aboriginal primary health care service

Drug class

Baseline N (%)

Study end N (%)

P*

Anti-platelet

3 (4.7%)

43 (68.3%)

< 0.001

Lipid lowering

4 (6.3%)

41 (65.1%)

< 0.001

ACEi/ARB

16 (25%)

40 (63.5%)

< 0.001

Oral hypoglycaemic

11 (17.2%)

21 (33.3%)

0.04

Beta blocker

3 (4.7%)

8 (12.7%)

0.09

Nitrate

2 (3.1%)

3 (4.8%)

0.49

Thiazide diuretic

0

2 (3.2%)

0.24

Calcium channel blocker

1 (1.6%)

1 (1.6%)

0.75

  1. Notes: ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker.
  2. * Chi Square test for change in proportion of participants prescribed each class of medication.
  3. † There was one death in the period following the AHC.
  4. Baseline = 3 years prior to date of AHC participation.
  5. Study end = 3 years following date of AHC participation.